The earnings call demonstrated strong revenue growth across all segments, with significant investments in new product launches and digital initiatives. However, there were notable challenges in the U.S. consumer market and concerns about the future impact of the Inflation Reduction Act on pharmaceutical sales.

Company Guidance

During the Bausch + Lomb Q3 2024 earnings call, the company provided guidance reflecting their strategic focus on execution and innovation. They reported a total company revenue of $1.196 billion for the quarter, showing a growth of 19% on a constant currency basis and 10% organically. The Vision Care segment experienced a 6% revenue increase, driven by a 12% growth in contact lenses. The Surgical segment saw a 12% revenue growth, while the Pharma segment achieved a substantial 76% growth, with organic growth at 25%. Adjusted gross margin increased by 170 basis points to 63%, and adjusted EBITDA, excluding acquired IP R&D, grew by 21% to $227 million. The company raised its full-year revenue guidance to a range of $4.725 billion to $4.825 billion, expecting a constant currency growth of approximately 16% to 18%. They also adjusted their Miebo revenue guidance upward to a range of $165 million to $170 million and maintained their full-year adjusted EBITDA guidance at $850 million to $900 million, excluding acquired IP R&D.

Strong Overall Revenue Growth

Total company revenue for the quarter was $1.196 billion, reflecting a growth of 19% and 10% on an organic basis.

Vision Care Segment Performance

Vision Care's third quarter revenue increased by 6%, with a notable 12% growth in contact lens revenue, driven by a 79% increase in Daily SiHy lenses.

Surgical Segment Growth

The Surgical segment saw a 12% increase in revenue, with consumables up 14% and premium IOLs up 23%.

Pharmaceutical Segment Surge

Pharma segment revenue was $306 million, representing a 76% growth, driven by Miebo and Xiidra revenues.

Positive Adjusted Gross Margin

Adjusted gross margin increased to 63%, up 170 basis points compared to the third quarter of 2023.

Launch of Digital Initiatives

The company launched Opal, a digital e-commerce marketplace, and continued to enhance its digital sales platform, Glimpse.

---

Bausch + Lomb Corporation (BLCO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BLCO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2025	2024 (Q4)	0.24 / -	0.24	―	―	―
Oct 30, 2024	2024 (Q3)	0.16 / 0.17	0.22	-22.73% (-0.05)
Jul 31, 2024	2024 (Q2)	0.13 / 0.13	0.18	-27.78% (-0.05)
May 01, 2024	2024 (Q1)	0.07 / 0.07	0.1	-30.00% (-0.03)
Feb 21, 2024	2023 (Q4)	0.17 / 0.24	0.23	4.35% (<+0.01)
Nov 01, 2023	2023 (Q3)	0.19 / 0.22	0.31	-29.03% (-0.09)
Aug 02, 2023	2023 (Q2)	0.15 / 0.18	0.29	-37.93% (-0.11)
May 03, 2023	2023 (Q1)	0.14 / 0.10	0.24	-58.33% (-0.14)
Feb 22, 2023	2022 (Q4)	0.22 / 0.23	0.39	-41.03% (-0.16)
Nov 02, 2022	2022 (Q3)	0.24 / 0.31	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

BLCO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 30, 2024	$20.76	$20.44	-1.54%
Jul 31, 2024	$16.87	$17.22	+2.07%
May 01, 2024	$14.54	$13.74	-5.50%
Feb 21, 2024	$14.59	$16.60	+13.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---